Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Drugs acting on the cardiovascular system
Tirabrutinib
Другие языки:

    Tirabrutinib

    Подписчиков: 0, рейтинг: 0
    Tirabrutinib
    Tirabrutinib.svg
    Clinical data
    Trade names Velexbru
    Other names GS-4059; ONO-4059
    Legal status
    Legal status
    • Rx-only (Japan)
    Identifiers
    • 6-Amino-9-[(3R)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one
    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    UNII
    ChEMBL
    Chemical and physical data
    Formula C25H22N6O3
    Molar mass 454.490 g·mol−1

    Tirabrutinib (brand name Velexbru) is a drug used for the treatment of autoimmune disorders and hematological malignancies.

    Tirabrutinib was approved in March 2020 in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma. In addition, tirabrutinib is in clinical development by Ono Pharmaceutical and Gilead Sciences in the United States, Europe, and Japan for autoimmune disorders, chronic lymphocytic leukemia, B cell lymphoma, Sjogren's syndrome, pemphigus, and rheumatoid arthritis.

    Tirabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase.


    Новое сообщение